Personal tools


AML: ICT01-101

A first-in-human, two-part, open-label, clinical study to assess the saftey, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/ refractory cancer (EVICTION ...Read More

Kolo-Rektal: Novartis CADPT01C12101

A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer.Read More